Session » 4M097: Systemic Sclerosis & Related Disorder – Clinical II: Cardiopulmonary Involvement (1830–1835)
- 2:30PM-4:00PM
-
Abstract Number: 1833
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial
- 2:30PM-4:00PM
-
Abstract Number: 1835
Frequency and Predictors of Meaningful Decline in Forced Vital Capacity During Follow up оf a Large Cohort of Systemic Sclerosis Associated Pulmonary Fibrosis Patients
- 2:30PM-4:00PM
-
Abstract Number: 1832
Reliability of Traditional Cardiovascular Risk Calculators in Predicting Risk of Cardiovascular Disease in Systemic Sclerosis
- 2:30PM-4:00PM
-
Abstract Number: 1834
Serum Interferon Chemokine Score Predicts Better Response to Immunosuppression in Systemic Sclerosis Related Interstitial Lung Disease
- 2:30PM-4:00PM
-
Abstract Number: 1830
Short- and Long-term Morbidity and Mortality Outcomes of African American Patients with Systemic Sclerosis-Related Interstitial Lung Disease
- 2:30PM-4:00PM
-
Abstract Number: 1831
Subtypes of Scleroderma Lung Involvement Associated with Burden of Disease and Outcomes